MK-5172 hydrateHCV NS3/4a protease inhibitor CAS# 1350462-55-3 |
- MK-5172 potassium salt
Catalog No.:BCC1764
CAS No.:1206524-86-8
- MK-5172
Catalog No.:BCC1762
CAS No.:1350514-68-9
- MK-5172 sodium salt
Catalog No.:BCC1765
CAS No.:1425038-27-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 1350462-55-3 | SDF | Download SDF |
| PubChem ID | 71576667 | Appearance | Powder |
| Formula | C38H52N6O10S | M.Wt | 784.92 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Grazoprevir hydrate | ||
| Solubility | DMSO : 50 mg/mL (63.70 mM; Need ultrasonic) H2O : < 0.1 mg/mL (insoluble) | ||
| SMILES | CC(C)(C)C1C(=O)N2CC(CC2C(=O)NC3(CC3C=C)C(=O)NS(=O)(=O)C4CC4)OC5=NC6=C(C=CC(=C6)OC)N=C5CCCCCC7CC7OC(=O)N1.O | ||
| Standard InChIKey | RXSARIJMSJWJLZ-CIAYNJNFSA-N | ||
| Standard InChI | InChI=1S/C38H50N6O9S.H2O/c1-6-22-19-38(22,35(47)43-54(49,50)25-13-14-25)42-32(45)29-18-24-20-44(29)34(46)31(37(2,3)4)41-36(48)53-30-16-21(30)10-8-7-9-11-27-33(52-24)40-28-17-23(51-5)12-15-26(28)39-27;/h6,12,15,17,21-22,24-25,29-31H,1,7-11,13-14,16,18-20H2,2-5H3,(H,41,48)(H,42,45)(H,43,47);1H2/t21-,22-,24-,29+,30-,31-,38-;/m1./s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development.
IC50 Value: 7.4 nM and 7 nM for genotype 1b and 1a respectively, in replicon system [1]
Target: HCV NS3/4a protease
in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2].
in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1].
Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1 References: | |||||
MK-5172 hydrate Dilution Calculator
MK-5172 hydrate Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.274 mL | 6.3701 mL | 12.7402 mL | 25.4803 mL | 31.8504 mL |
| 5 mM | 0.2548 mL | 1.274 mL | 2.548 mL | 5.0961 mL | 6.3701 mL |
| 10 mM | 0.1274 mL | 0.637 mL | 1.274 mL | 2.548 mL | 3.185 mL |
| 50 mM | 0.0255 mL | 0.1274 mL | 0.2548 mL | 0.5096 mL | 0.637 mL |
| 100 mM | 0.0127 mL | 0.0637 mL | 0.1274 mL | 0.2548 mL | 0.3185 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50 Value: 7.4nM and 7nM for genotype1b and 1a respectively, in replicon system [1] MK-5172 is a novel P2-P4 quinoxaline macrocyclic HCV NS3/4a protease inhibitor currently in clinical development. in vitro: In biochemical assays, MK-5172 was effective against a panel of major genotypes and variants engineered with common resistant mutations observed in clinical studies with other NS3/4a protease inhibitors. In the replicon assay, MK-5172 demonstrated subnanomolar to low-nanomolar EC50s against genotypes 1a, 1b, and 2a [2]. in vivo: In rats, MK-5172 showed a plasma clearance of 28 ml/min/kg and plasma half-life of 1.4 hr. When dosed p.o. at 5 mg/kg, the plasma exposure of MK-5172 was good with an AUC of 0.7 uM.hr. The liver exposure of the compound was quite good (23 uM at 4 hr), and MK-5172 remained in liver 24 hr after a single p.o. 5 mg/kg dose. At 24 hr, the liver concentration of MK-5172 was 0.2 uM, which was over 25-fold higher than the IC50 in the replicon assay with 50% NHS. When dosed to dogs, MK-5172 showed low clearance of 5 ml/min/kg and a 3 hr half-life after i.v. 2 mg/kg dosing and had good plasma exposure (AUC=0.4 uM.hr) after a p.o. 1 mg/kg dose [1]. Clinical trial: Evaluation of Hepatic Pharmacokinetics for MK-5172 in Participants With Chronic Hepatitis C . Phase1
- Clopidogrel bisulfate
Catalog No.:BCC8917
CAS No.:135046-48-9
- Z-Hyp-OH
Catalog No.:BCC3257
CAS No.:13504-85-3
- Pseudotropine
Catalog No.:BCN1932
CAS No.:135-97-7
- 2,2'-Dithiobisbenzanilide
Catalog No.:BCC8497
CAS No.:135-57-9
- Taccalonolide AJ
Catalog No.:BCN2971
CAS No.:1349904-82-0
- SAR245409
Catalog No.:BCC2534
CAS No.:934493-76-2
- 4-P-PDOT
Catalog No.:BCC6900
CAS No.:134865-74-0
- 8-M-PDOT
Catalog No.:BCC6901
CAS No.:134865-70-6
- 6''-O-Acetylglycitin
Catalog No.:BCN3866
CAS No.:134859-96-4
- A 412997 dihydrochloride
Catalog No.:BCC6224
CAS No.:1347744-96-0
- Linderane
Catalog No.:BCN5023
CAS No.:13476-25-0
- Lamivudine
Catalog No.:BCC3801
CAS No.:134678-17-4
- MK-5172
Catalog No.:BCC1762
CAS No.:1350514-68-9
- Repaglinide
Catalog No.:BCC2504
CAS No.:135062-02-1
- kb-NB77-78
Catalog No.:BCC5462
CAS No.:1350622-33-1
- Camelliaside A
Catalog No.:BCN3871
CAS No.:135095-52-2
- Fmoc-Nva-OH
Catalog No.:BCC3302
CAS No.:135112-28-6
- Z-Tyr-OMe
Catalog No.:BCC2746
CAS No.:13512-31-7
- 2',7-Dihydroxy-5,8-dimethoxyflavanone
Catalog No.:BCN4041
CAS No.:1351338-14-1
- H-Sar-OMe.HCl
Catalog No.:BCC3335
CAS No.:13515-93-0
- H-DL-Ala-OMe.HCl
Catalog No.:BCC2854
CAS No.:13515-97-4
- Sarpogrelate hydrochloride
Catalog No.:BCC5247
CAS No.:135159-51-2
- Amooracetal
Catalog No.:BCN6876
CAS No.:1351617-73-6
- 21,23:24,25-Diepoxy-21,23-dimethoxytirucall-7-en-3-one
Catalog No.:BCN1581
CAS No.:1351617-74-7
